Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
June 20, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
The reiteration of an Overweight rating and the maintenance of a $7 price target by a reputable analyst can boost investor confidence in Taysha Gene Therapies. This positive sentiment is likely to have a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100